NVO股价承压，因市场认为其战略计划不够大胆或推进不够快，不过40美元处存在技术支撑。
逐段跳播
现在来谈谈Novo，也就是此前的Novo Nordisk。该公司股价今早承压。市场似乎对Novo公布的下一阶段战略计划感到不满。
Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.
显然，他们的减肥药曾需求旺盛，至少在初期阶段是如此。但如今，竞争已经进入这一领域，并抢走了他们的部分市场份额。
It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.
但他们计划到2025年推出五款以上成功的药物，并在2035年前实现约230亿美元的预期销售额。然而，市场似乎再次希望这些产品能有更快的时间表。
But they plan to launch more than five successful drugs by 2025, and achieve about $23 billion in projected sales by 2035. However, it appears once again that the market wants a faster timeline for these products.
这只股票已经下跌，但真正有意思的是，如果你看月线图上的40美元关口，你会发现它代表该股的200月移动均线。事实上，我想自2004年或2003年以来，该股从未跌破这一均线。因此，40美元附近存在一个技术支撑位，尽管基本面仍然相对疲弱。
This stock has declined, but what is really interesting is , if you look at the $40 level on the monthly chart , you will find that it represents the stock's 200-month moving average .
In fact, the stock hasn't traded below this average since 2004 or 2003, I think. Therefore, there is a technical support level at around $40, although the fundamentals are still relatively weak.
但他们对自己即将推出的一些药物持乐观态度。他们希望到2030年在全球覆盖超过6000万名患者，同时将产能提高十倍，以便为额外1500万名患者提供肥胖症口服治疗，他们计划在未来两年内逐步推出。
But they are optimistic about some of the drugs they will be releasing soon. They are looking to reach more than 60 million patients globally by 2030, in addition to increasing their manufacturing capacity tenfold to provide oral treatments for obesity to an additional 15 million patients they plan to roll out over the next two years.
所以，他们是有战略的，但并没有市场所期望的那么大胆，这就是今天股价下跌的原因。
So, they have a strategy, but it's not as bold as the market had hoped, and that's why we're seeing stocks decline today.
这个频道对 $NVO 的历次判断
Schwab Network 在这只股票上共 2 条判断，这里只列相邻的几条。